Clopidogrel resistance and its relevance: Current concepts [PDF]
Journal of Family Medicine and Primary CareClopidogrel is the most widely used P2Y12 receptor inhibitor (P2Y12i) as a part of dual antiplatelet therapy along with aspirin. Clopidogrel is a pro-drug and is metabolized to its active metabolite by the hepatic enzyme cytochrome P4502C19 (CYP2C19 ...
Akshyaya Pradhan +3 more
doaj +5 more sources
TMAO: a potential mediator of clopidogrel resistance [PDF]
Scientific Reports, 2021 Trimethylamine-N-oxide (TMAO) can activate platelets and increase thrombosis risk in clinical and experimental models. Meanwhile, the patients with coronary artery disease have higher serum TMAO level.
Ruisong Ma +5 more
doaj +6 more sources
Aspirin and clopidogrel resistance; a neglected gap in stroke and cardiovascular practice in Iran: a systematic review and meta-analysis [PDF]
Thrombosis Journal, 2023 Objective Antiplatelet drugs, such as Aspirin and Clopidogrel (Plavix) are effective in the primary prevention of thromboembolic events. They are commonly used to reduce the risk of recurrence of thromboembolism.
Mohammad Parsa-kondelaji +1 more
doaj +3 more sources
Lower Plasma miR-223 Level Is Associated with Clopidogrel Resistance in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis [PDF]
Journal of Interventional Cardiology, 2023 Objectives. To evaluate the relationship between the plasma miR-223 expression level and clopidogrel resistance in acute coronary syndrome (ACS) patients. Methods.
Hang Cheng +9 more
doaj +3 more sources
Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients [PDF]
Vascular Health and Risk Management, 2023 Rakhmad Hidayat,1– 3 Al Rasyid,2,3 Salim Harris,2,3 Alida Harahap,2 Herqutanto,2 Melva Louisa,2 Erlin Listiyaningsih,4 Aldy Safruddin Rambe,5 Tonny Loho6 1Doctoral Program in Medical Sciences Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia;
Hidayat R +8 more
doaj +3 more sources
Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome [PDF]
Indian Heart JournalAim: The genetic polymorphism of CYP2C19 influences clopidogrel metabolism and resistance. Aim was to assess the association between CYP2C19 loss of function variation, clopidogrel resistance based on platelet reactivity units and clinical outcomes ...
Heemanshu Lodhi +7 more
doaj +3 more sources
Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment [PDF]
Frontiers in Neurology, 2021 Background: The factors associated with clopidogrel resistance in patients with stroke recurrence receiving single or dual antiplatelet treatment (SAPT or DAPT) may differ.
Hyun Goo Kang +4 more
doaj +3 more sources
The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention [PDF]
Frontiers in Cardiovascular Medicine, 2023 Despite patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel therapy, some patients still experience major adverse cardiovascular events (MACEs).
Astuti Giantini +13 more
doaj +3 more sources
Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI) [PDF]
Pharmacology Research & Perspectives, 2021 Clopidogrel resistance is an important risk factor of ischemic event recurrence after optimal antiplatelet therapy. This study aims to investigate the role of CYP2C19 gene DNA methylation as one of the epigenetic factors for the risk of clopidogrel ...
Renan Sukmawan +7 more
doaj +3 more sources
Clopidogrel resistance: The way forward
Indian Heart Journal, 2014 Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj +3 more sources